Using this company's weight loss medication helps maintain the effect.

Eli Lilly and Company announced on Thursday that in a late-stage clinical trial, its highly anticipated weight loss pill helped patients maintain most of their weight loss results after switching from the company's injection Zepbound or competitor injection Wegovy from Novo Nordisk. BMO Capital Markets analyst Evan Seigerman stated that the positive results of the trial could provide Eli Lilly and Company with a "unique opportunity to gain a share of revenue from the chronic treatment market for semaglutide, the active ingredient in Novo Nordisk's Wegovy and diabetes injection Ozempic."